Press Releases

Jan 28, 2020

FDA accepts for priority review Dupixent® (dupilumab) for children aged 6 to 11 years with moderate-to-severe atopic dermatitis

If approved, Dupixent would be the first biologic medicine available in the U.S. for these children
Jan 23, 2020

Sanofi Completes Acquisition of Synthorx, Inc.

* Synthorx, Inc. is now a fully owned subsidiary of Sanofi
Dec 9, 2019

Sanofi awarded $226 million by US government to expand pandemic influenza preparedness

- U.S.-based, state of the art facilities to be established for sustainable production of adjuvanted recombinant vaccine for use in the event of a pandemic
Nov 21, 2019

Pivotal data from Phase 3 study of sutimlimab in cold agglutinin disease to be presented at ASH 2019 late-breaking session

- Sutimlimab, an investigational targeted C1s inhibitor, met its primary efficacy endpoint in Phase 3 trial for patients with cold agglutinin disease (CAD)
Nov 20, 2019

Sanofi and Aetion launch enterprise-wide collaboration to advance regulatory submissions using real-world evidence

Show per page